



## **ADL Bionatur Solutions Signs Contract Extension of up to EUR 6.2 Million**

- Extension of an existing contract with a US-based customer for the manufacture and supply of a high value-added product made by fermentation
- ADL to increase the supplied quantity as of September 2018

**León, Spain, 18 June 2018-** ADL Bionatur Solutions (MAB:ADL), through its subsidiary ADL Biopharma, has signed an extension of an existing contract for the manufacture and supply of a high value-added product for a US-based company. The customer is a leading international company in the field of innovative high value-added products made by fermentation. The contract relates to the development of a product with applications in several industries, including cosmetics.

The extension will be implemented in September 2018 and will entail an increase in both the quantity of the fermented product and the turnover. The product will be made at ADL's plant in León, using an additional fermenter for 15 months. Sales are estimated to increase by EUR 4.5 million to EUR 6.2 million.

Pilar de la Huerta, CEO of ADL Bionatur Solutions, commented: "We are very pleased with the signing of this contract, which consolidates and expands our fermentation business line and is an acknowledgement of the experience, talent and technical expertise of the renewed ADL Biopharma. At the same time, it enhances the use of our facilities in León. We highly appreciate that current customers increase their demand which confirms the general trend we are seeing in the industry."

ADL Bionatur Solutions expects a 500 percent increase in revenue over the next three years, while the Company's EBITDA is estimated to reach its break-even point in the course of the current 2018 financial period.

Overall, 65 % of ADL's long-term sales are backed by existing contracts. This figure is estimated to rise to 85 % under the new fermentation agreements ADL expects to sign in the coming months.

Furthermore, ADL Bionatur Solutions announced last Thursday a capital increase of up to EUR 15 million aimed at qualified investors, with a view to continuing the Company's business growth and expand into new markets as defined in ADL's strategic plan.



### **About ADL Bionatur Solutions**

ADL Bionatur Solutions, controlled by the investment fund Black Toro Capital (BTC) with 85% of the capital, is the company resulting from the merger of ADL Biopharma (formerly, Antibióticos de León) and the Jerez-based company Bionaturis. This merger involves melding into a single entity the specialization in R&D in health products and services and the industrial production by fermentation and manufacturing capacity. ADL Bionatur Solutions has been listed on the MAB, Spain's Alternative Stock Market, since May 2018. [www.adlbionatur.com](http://www.adlbionatur.com)